We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Rapid COVID-19 Antigen Tests Less Effective at Detecting SARS-CoV-2 in People with Low Virus Levels, Finds Study

By LabMedica International staff writers
Posted on 22 Oct 2020
Researchers from the Erasmus University Medical Center (Rotterdam, the Netherlands) have cautioned that not all rapid COVID-19 antigen tests that provide results within 30 minutes may be equally effective at detecting the SARS-CoV-2 virus.

Their suggestion was based on data gathered from drive through testing stations using rapid antigen detection tests (RDTs), RT-PCR and virus culture, with the aim of assessing the ability of RDTs to detect infectious cases. More...
Antigen-based assays detect specific surface proteins, or antigens, on SARS-CoV-2 particles, and are easy to use and inexpensive to produce. The researchers used five commercially available rapid antigen assays on samples from 1,754 people who had already tested positive for the SARS-CoV-2 virus with the standard PCR test, which is highly sensitive but slow.

The team found that the detection limits of the five commercially available RDTs differed considerably, impacting the translation into the detection of infectious cases. The two most sensitive tests detected the SARS-CoV-2 virus more than 97% of the time, whereas the least sensitive test detected the novel coronavirus in about 75% of the cases. All the samples came from people with COVID-19 symptoms, who tend to have high levels of the SARS-CoV-2 virus. Based on their findings, the researchers have cautioned that rapid antigen tests may be less effective at picking up the presence of the SARS-CoV-2 virus in people with low levels of the virus. The researchers have recommended careful fit-for-purpose testing before implementation of antigen RDTs in routine testing algorithms as part of the COVID-19 response.

Related Links:
Erasmus University Medical Center


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Electrolyte Analyzer
BKE-B
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.